Nanotechnology Challenges in Targeted Delivery of Biopharmaceutics

Abstract

Event Abstract Back to Event Nanotechnology Challenges in Targeted Delivery of Biopharmaceutics Costas Kiparissides1*, Olga Kammona1 and Vassilis Karageorgiou1 1 Aristotle University of Thessaloniki and Chemical Process Engineering Research Institute, Department of Chemical Engineering, Greece New Peptidic/Proteinic (P/P) drugs are being discovered every day and their increased availability offers new ways to treat and prevent diseases. However, the structure, physicochemical properties, stability, pharmacodynamics and pharmacokinetics of these new biopharmaceutics place stringent demands on the way they are delivered into the body. Additionally, P/P drugs do not easily cross mucosal surfaces and biological membranes, are easily denatured or degraded, prone to rapid clearance in the liver and other body tissues, and require precise dosing. Major goals of nanomedicine in terms of controlled delivery of biopharmaceutics, are the maximization of their bioavailability and efficacy, the control of pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity and biorecognition as well as the overcoming of obstacles arising from low solubility, degradation, fast clearance rates, relatively short-lasting biological activity and inability to cross biological barriers. The above goals are expected to be achieved, through the development of targeted delivery systems that can be selectively delivered to specific areas in the human body. However, since P/P drug characteristics differ substantially with respect to chemical composition, molecular size, hydrophilicity, bioavailability, optimum concentration range, etc., the essential characteristics that identify the efficiency of the delivery systems are highly complex. Thus, their development has to be pursued as a multi disciplinary effort, firmly built on extensive experience in polymer science, pharmacochemistry, pharmacology, molecular biology, bioconjugate chemistry and toxicology. Recent advances in the delivery of biopharmaceutics deal with the development of synthetic nanometer sized targeted delivery systems in the form of nanocarriers (e.g., polymeric or hybrid nanoparticles, nanogels, lipid based vesicles, dendrimers) and molecular carriers (e.g., polyelectrolyte complexes, polymer-P/P drug complexes). Targeted delivery systems can have multiple functions, a key one being their ability to recognize specific molecules which can be located either in the membrane of target cells, or in specific compartments within the cell. The carrier-based drug delivery systems can improve the bioavailability and diminish the toxicity of P/P drugs, control their release profile and make alternative administration routes possible. A challenging objective of targeted delivery is the development of novel nanocarriers and molecular carriers for the targeted delivery of biopharmaceutics via oral, nasal and Blood Brain Barrier (BBB) crossing administration routes. Keywords: Nanotechnology, Targeted Drug Delivery, Biopharmaceutics Conference: 8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010, Thessaloniki, Greece, 1 Oct - 5 Oct, 2010. Presentation Type: Invited speaker Topic: Nanopharmacology / Nanomedicine Citation: Kiparissides C, Kammona O and Karageorgiou V (2010). Nanotechnology Challenges in Targeted Delivery of Biopharmaceutics. Front. Pharmacol. Conference Abstract: 8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010. doi: 10.3389/conf.fphar.2010.60.00142 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 05 Mar 2011; Published Online: 04 Nov 2010. * Correspondence: Dr. Costas Kiparissides, Aristotle University of Thessaloniki and Chemical Process Engineering Research Institute, Department of Chemical Engineering, Thessaloniki, 54124, Greece, cypress@cperi.certh.gr Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Costas Kiparissides Olga Kammona Vassilis Karageorgiou Google Costas Kiparissides Olga Kammona Vassilis Karageorgiou Google Scholar Costas Kiparissides Olga Kammona Vassilis Karageorgiou PubMed Costas Kiparissides Olga Kammona Vassilis Karageorgiou Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.